Our focus is deeply rooted
in severe lung disease

R&D day, March 2022 - Featuring Prof. Toby Maher, Prof. Maureen Horton and Dr Gerry Coghlin

Financial reports

Interim report, Q1 Read more

Upcoming events

2022-05-18 - 2022-05-19

ABG Life Science Summit

2022-05-19

Redeye investor forum, Gothenburg

Read more

Latest news

See all

MedNous article: A surprise finding in the clinic

Every once in a while a discovery in the clinic exceeds researchers’ expectations. Read More

Patient insights to shape development of a dCBT for IPF patients

Survey analysis of the psychological aspects of living with… Read More

About us

Vicore is a clinical-stage pharmaceutical company focused on severe lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Fibrotic lung disease

Idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis and is a severe and devastating disease with no known cause. It is characterized by a shrinking of the lungs due to the irreversible formation of fibrosis (i.e. scar tissue) causing stiffness, an irreversible loss of lung function and difficulty in breathing.

Our Vision

Vicore’s vision is to remove the pain and suffering caused by severe lung disease. As a company, we pride ourselves on our collaborative approach to science and are committed to working closely with the patient community, scientific experts and clinicians to find innovative solutions that meet their needs.